NRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
Enrollment continues in the Phase 2b/3 clinical trial evaluating NRX-101 in Suicidal Treatment-Resistant Bipolar Depression; data expected in 4Q 2023National educational campaign launched to further... | May 16, 2023